Lymphatic Malformation (Cystic Hygroma)

Back

Background

First described by Wernher in 1843, cystic hygroma (CH) is a cystic lymphatic lesion that can affect any anatomic subsite in the human body.[1] Currently, this lesion is more commonly referred to as a lymphatic malformation (LM). LMs usually affect the head and neck (~75%), with a predilection for the left side. Within the neck, the posterior triangle tends to be most frequently affected. Approximately 20% of LMs occur in the axilla; less common subsites include the mediastinum,[2] groin, and retroperitoneum.

LM is synonymous with cystic lymphangioma, which is also known as a macrocystic lymphatic malformation and was first described in 1828 by Redenbacker.

Pathophysiology

LMs are thought to arise from a combination of the following:

These lymphatic rests can penetrate adjacent structures or dissect along fascial planes and eventually become canalized. These spaces retain their secretions and develop cystic components because of the lack of a venous outflow tract. The nature of the surrounding tissue determines whether the lymphangioma is capillary, cavernous, or cystic.

LMs tend to form in loose areolar tissue, whereas capillary and cavernous forms of lymphangiomas tend to form in muscle. Studies using cell proliferation markers have demonstrated that lymphangioma enlargement is related more to engorgement than to actual cell proliferation. Molecular studies suggest that vascular endothelial growth factor C (VEGF-C) and its receptors may play an important role in the development of LMs.[3]

In addition to congenital development, LMs can be acquired. They can arise from trauma (including surgery), inflammation, or obstruction of a lymphatic drainage pathway.

Etiology

Karyotypic abnormalities are present in 25-70% of children with LM. LM has been noted to be more common in persons with Turner syndrome, Down syndrome, Klinefelter syndrome, and trisomy 18 and 13, though these are not considered to be causative.

In addition, several nonchromosomal disorders, including Noonan syndrome, Fryns syndrome, multiple pterygium syndrome, and achondroplasia, are associated with an increased incidence of LM. Intrauterine alcohol exposure has been associated with the development of LM. Dissolution of bone caused by either LM or hemangiomas is termed Gorham-Stout syndrome.

Epidemiology

The incidence of LM is estimated to be one case per 6000-16,000 live births.

Most LMs (50-65%) are evident at birth, and 80-90% of them present by age 2 years. Some authors believe that all LMs are present at birth, even though they may not have fully manifested at that time. LM can be visualized by means of abdominal ultrasonography (US) by 10 weeks' gestation, though transvaginal US provides superior detail. Fast-spin magnetic resonance imaging (MRI) can also be used to determine the extent of fetal LM. Elevated alpha fetoprotein levels in amniocentesis fluid has been reported in pregnancies with LM.

The sex distribution is equal. Most series report no racial predominance, though a decreased incidence in African Americans has been described.

Prognosis

In some series, the reported mortality has been as high as 2-6%, usually secondary to pneumonia, bronchiectasis, and airway compromise. Obviously, this figure is pertinent in the larger-sized lesions.

As would be expected, morbidity depends on the anatomic location of the LM. In general, morbidity is related to cosmetic disfigurement and impingement on other critical structures, such as nerves, vessels, lymphatics, and the airway.

Unlike hemangiomas, LMs do not commonly resolve spontaneously. Recurrence is rare when all gross disease is removed. If residual tissue is left behind, the expected recurrence rate is approximately 15%.

In antenatal CH, diagnosis after 30 weeks' gestation is considered a positive prognosticator. A study by Lejeunesse et al involving 69 fetuses with LMs diagnosed in the first trimester suggested that the following were predictors of a poor outcome[4] :

A study by Sanhal et al found that fetuses with septated LMs had with poor perinatal outcomes.[5]

History

The presenting signs and symptoms of a lymphatic malformation (LM) vary, depending on the lesion's location.

The microcystic form tends to predominate over macrocystic LM in the oral cavity and oropharynx. Microcystic LMs commonly appear as clusters of clear, black, or red vesicles on the buccal mucosa or tongue. Macrocystic LMs tend to predominate below the mylohyoid muscle and can involve both the anterior and posterior triangles of the neck. The cysts are typically large and thick-walled and have little involvement of surrounding tissue. The overlying skin can take on a bluish hue or may appear normal.

LMs often present after a sudden increase in size secondary to infection or intralesional bleeding. Spontaneous decompression or shrinkage is uncommon.

Rarely, children with LMs display symptoms of newly onset obstructive sleep apnea syndrome (OSAS). This situation may involve children with LM or other space-occupying lesions of the supraglottic or paraglottic region. Suprahyoid lymphangiomas tend to cause more breathing difficulties than infrahyoid lesions.

Potentially life-threatening airway compromise that manifests as noisy breathing (stridor) and cyanosis is a possible symptom of lymphangiomas.

Feeding difficulties, as well as failure to thrive, may alert the clinician to a potential lymphangioma. This is especially true when the lesion affects structures of the upper aerodigestive tract.

Rare locations, such as the middle ear, have been reported.[6]

Physical Examination

On physical examination, the typical LM is a soft, painless, compressible (doughy) mass that usually transilluminates.

In children who present with LM of the neck, closely evaluate for tracheal deviation or other evidence of impending airway obstruction. Closely inspect the tongue, oral cavity, hypopharynx, and larynx; any involvement of these structures may lead to airway obstruction.

Referral to an airway expert (otolaryngologist) to potentially perform a fiberoptic airway evaluation is justified in patients with a lymphatic malformation.

Complications

Complications of LMs include the following:

Laboratory Studies

Studies have suggested that fluorescent in-situ hybridization (FISH) can be used to evaluate for lymphatic malformation (LM) in antenatal chromosomal analysis. Chromosomes 13, 18, 21, X, and Y are specifically mentioned.[7]

Imaging Studies

Magnetic resonance imaging (MRI), computed tomography (CT), and ultrasonography (US) are all helpful in delineating the nature of a cystic neck mass. CT and MRI reveal a ringlike margin enhancement with sharp demarcation of cystic areas. The cystic areas tend to appear circumscribed and discrete. A poorly defined isodense mass that obscures muscle and fatty planes is more consistent with a microcystic lymphatic malformation than with an LM.

Magnetic resonance imaging

MRI is the consensus study of choice. It provides the best soft-tissue detail and can delineate the relation of the lesion to underlying structures. Contrast can be used to differentiate hemangiomas from lymphangiomas. On MRI, LMs appear hyperintense on T2-weighted images and hypointense on T1-weighted images.

Computed tomography

CT is faster than MRI and may be more readily available. It carries the risk of radiation exposure, and detail is lost if the LM is surrounded by tissue of similar attenuation. Contrast helps to enhance cyst-wall visualization and the relation to surrounding blood vessels. On CT scans, LMs appear isodense to cerebrospinal fluid (CSF). (See the image below.)



View Image

Reconstruction of CT in sagittal dimension. This patient was intubated because of respiratory distress caused by the large lymphatic malformation.

Ultrasonography

US is the least invasive study. It is very useful in demonstrating the relationship of LM to the surrounding structures. US has limited ability in assessing mediastinal and retropharyngeal structures. It can be used to detect LM in utero. Echographic visualization of multiple septa in fetal LM has been postulated to be a poor prognostic indicator.[5]

Plain radiography

With any large mass of the head and neck, airway radiography (high-kilovolt anteroposterior and lateral neck radiographs or airway fluoroscopy) can be helpful in delineating possible airway compromise. Plain radiography is a reasonable initial imaging modality in the evaluation of a neck mass with a potential airway manifestation.

Lymphoscintigraphy

A case report highlighted the ability to visualize LM by means of lymphoscintigraphy.[8]

Procedures

Several studies have documented the use of US-guided endoscopic biopsy for diagnosis of gastrointestinal LMs.[9]

Histologic Findings

LMs are composed of large irregular sinuses with a single layer of flattened epithelial lining and fibrous adventitial coats. The thickness of the vessel wall varies, with both striated and smooth muscle components. 

Although most LMs are multicystic, a unilocular cyst is found in approximately 10% of cases. Cysts can range from 1 mm to several centimeters in size and are filled with clear- to straw-colored fluid, which is eosinophilic and protein-rich. Individual cysts may be isolated or may freely communicate. The surrounding stroma is fibrous or fatty and may contain lymphoid aggregates, smooth muscle, or other local tissues.

LMs may contain multiple subtypes (eg, capillary and cavernous) and, in these instances, are categorized according to the predominant subtype. In addition, lesions with a hemangiomatous component are considered hemangiolymphangiomas. Hemorrhage into the cyst is common and can be secondary to trauma or spontaneous bleeding.

Capillary LMs contain capillary-sized lymphatic channels that involve the epidermis. Cavernous LMs infiltrate surrounding structures and are dilated lymphatic channels. Macrocystic LMs are cystic masses lined by a single layer of endothelium with a connective-tissue stroma.

Staging

Classification has been marred by a historical lack of conformity. In 1877, the first system was proposed by Wegener. In 1982, Mulliken and Glowacki presented a cell-based classification of pediatric vascular lesions that is currently used by many authors.[10] Their system stratified lesions into two types: hemangiomas and vascular malformations, with LMs falling into the latter category. The World Health Organization (WHO) recognizes three types of lymphangiomas: capillary, cavernous, and cystic.

Central to any discussion of LM is the understanding that it is synonymous with macrocystic lymphatic malformation and cystic lymphangioma.

Giguère et al proposed categorizing lymphangiomas on the basis of the size of the cystic component, as follows[11] :

De Serres et al proposed the following system for staging of LMs of the head and neck[12] :

Approach Considerations

Although some authors have reported watchful waiting for lymphatic malformations (LMs), this should be considered only in patients who are asymptomatic. Medical treatment of LMs consists of the administration of sclerosing agents, such as OK-432 (an inactive strain of group A Streptococcus pyogenes), bleomycin, pure ethanol, bleomycin, sodium tetradecyl sulfate, and doxycycline.[13] ​ Guidelines for the use of percutaneous sclerotherapy to treat LMs of the head and neck have been developed by the Society of NeuroInterventional Surgery (SNIS).[14]

An infected LM should be treated with intravenous antibiotics, and definitive surgery should be performed once the infection has resolved. Incision and drainage or aspiration results in only temporary shrinkage, and subsequent fibrosis can further complicate the resection. Radiotherapy has not been demonstrated to be effective. Some authors maintain that the preferred treatment of all LMs is surgical resection, positing that only resection can truly offer the potential for cure.

Medical Care

OK-432

Although not currently approved by the US Food and Drug Administration (FDA), OK-432 has been reported to be capable of successfully treating LM.[15] The mechanism of action is proposed to be an inflammatory response to the inactive bacteria, leading to fibrosis of the hygroma. OK-432 may be a viable option for large unilocular cysts.

Currently, OK-432 is available in the United States only by protocol. It does not work well for small cysts.[16] Because the procedure for using OK-432 involves aspiration prior to injection of the sclerosant, some have hypothesized that the true effect is from the aspiration.

Bleomycin

Bleomycin has been considered a poor choice because of its toxicity (pulmonary fibrosis); LM is a benign disease, and other less toxic treatment options are available. Niramis et al studied 70 patients who underwent sclerotherapy with bleomycin; 83% obtained an excellent or good result, 43% had adverse reactions, and three patients died.[17]

Sainsbury et al studied 75 patients, 83% of whom had a complete or significant response. Five adverse reactions were reported, with no severe morbidity or mortality (to include pulmonary fibrosis).[18]

Alcohol

Absolute alcohol as a sclerosing agent has been used with some success in some patients; alcohol works well in vascular malformations. Imperizzilli et al studied computed tomography (CT)-guided ethanol injection and obtained complete resolution in seven of eight patients without complications.[19]

Interferon alfa-2a

This has been used in the treatment of hemangiomas, and its use has been proposed in lymphangiomas. However, its efficacy has never been documented, and it carries a serious side-effect profile.

Fibrin sealant

The use of a fibrin sealant after aspiration of LM has been reported in the literature.

Doxycycline

Doxycycline has been reported as a potential sclerotherapy agent, with both safety and efficacy. Like most other sclerosant agents, it has shown the highest efficacy in macrocystic lesions and the lowest efficacy in microcystic ones.[20]

Sildenafil

A limited case series has been reported using sildenafil for severe lymphatic malformations. A prospective trial has been performed, which did not demonstrate a significant effect on LM.[21]

Sirolimus

Sirolimus has been utilized in several small series, but the optimal dose and duration have not been identified.[22, 23, 24, 25, 26]

Surgical Care

The mainstay of treatment of LMs is surgical excision.[27] Although surgery is the criterion standard for treatment, both the operating team and the family of the patient should go forward with the knowledge that LM is a benign lesion. If acute infection occurs prior to resection, surgery should be delayed at least 3 months.

The surgical team should attempt to remove the LM completely or, failing that, to remove as much as possible, sparing all vital neurovascular structures. Complete excision has been estimated to be possible in roughly 40% of cases.

LMs are ideally removed in a single procedure because secondary excisions are complicated by fibrosis and distorted anatomic landmarks.

Microcystic lesions are much more difficult to remove because of their intimate association with nearby tissues. Laser therapy is a recent advancement in the treatment of microcystic lesions.

The exceptions to excision at the time of diagnosis are few and include premature infants who are small in size and those with involvement of crucial neurovascular structures that are small and difficult to identify (eg, facial nerve). If no airway obstruction is present, surgery can be delayed until the child is aged 2 years or older, especially when the operation will be around the facial nerve in the parotid area.

Signs of airway obstruction necessitate surgical evaluation at the time of diagnosis. In emergency situations, aspiration with an 18-gauge or 20-gauge needle may obviate the need for an emergency tracheostomy.

Although traditional wisdom has dictated that LMs should not be aspirated, a study by Burezq et al documented success with serial aspiration of LM.[28] In this series, 14 patients were treated with aspiration alone (three needed multiple aspirations), with a mean follow-up of 5.75 years. No failures were reported. This technique may hold promise for the future management of LM. Other authors contend that aspiration has no role and believe that aspiration is often followed by recurrence, hemorrhage, or infection.

Radiofrequency ablation (RFA) has been advocated for use with intraoral LMs, especially microcystic lesions. Kim et al reported high long-term success rates with RFA (median follow-up, 47 months), with 81% of patients not requiring further treatment.[29]

Magnetic resonance–controlled laser-induced interstitial thermotherapy is a newer therapy that has been proposed for treatment of LM.

LM can present on routine antenatal ultrasonography (US) as a large obstructing airway mass, as can other pathologic conditions (eg, teratoma or rhabdomyosarcoma). If such a mass is visible on US, MRI should be performed to delineate the mass further. In these cases, a multispecialty team, including a high-risk obstetrician, pediatric otolaryngologist, pediatric surgeon, and neonatologist, should be present at the ex-utero intrapartum treatment (EXIT) procedure.

A planned cesarean delivery is performed, and intubation or tracheostomy is used to establish an airway. Extracorporal membrane oxygenation (ECMO) should also be available. Excision of the LM is delayed until the child is stable. Intrauterine cyst aspiration to facilitate vaginal delivery has been reported in the literature.

Complications

Complications from surgical excision of an LM are myriad and are related to the location and structures adjacent to the mass; these include the following:

Activity

Patients with LM should be directed to avoid direct trauma to the area because intralesional bleeding or infection can be precipitated by trauma.

Consultations

Depending on the anatomic location of the lesion, referral to a surgeon or surgical specialist is appropriate. In patients with LM of the head and neck, referral to an otolaryngologist is appropriate.

Author

Jason L Acevedo, MD, Otoloaryngologist-Head and Neck Surgeon

Disclosure: Nothing to disclose.

Coauthor(s)

Holly L Neville, MD, Associate Professor of Clinical Surgery, Division of Pediatric Surgery, University of Miami, Leonard M Miller School of Medicine

Disclosure: Nothing to disclose.

Rahul K Shah, MD, FACS, FAAP, Associate Professor of Otolaryngology and Pediatrics, Associate Surgeon-in-Chief, Medical Director, Peri-operative Services, Children's National Medical Center, George Washington University School of Medicine and Health Sciences; Attending Physician, Department of Otolaryngology, Children's National Medical Center

Disclosure: Nothing to disclose.

Specialty Editors

Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

John E McClay, MD, Associate Professor of Pediatric Otolaryngology, Department of Otolaryngology-Head and Neck Surgery, Children's Hospital of Dallas, University of Texas Southwestern Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Ravindhra G Elluru, MD, PhD, Professor, Wright State University, Boonshoft School of Medicine; Pediatric Otolaryngologist, Department of Otolaryngology, Dayton Children's Hospital Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

Orval Brown, MD Director of Otolaryngology Clinic, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center at Dallas

Orval Brown, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics, American Bronchoesophagological Association, American College of Surgeons, American Medical Association, American Society of Pediatric Otolaryngology, Society for Ear, Nose and Throat Advances in Children, and Society of University Otolaryngologists-Head and Neck Surgeons

Disclosure: Nothing to disclose.

William K Chiang, MD Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD, is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Michael D Poole, MD, PhD Consulting Staff, Georgia Ear Institute

Michael D Poole, MD, PhD, is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, and American Society for Microbiology

Disclosure: Nothing to disclose.

References

  1. Miceli A, Stewart KM. Lymphangioma. Treasure Island, FL: StatPearls; 2018.
  2. Ueno S, Fujino A, Morikawa Y, Iwanaka T, Kinoshita Y, Ozeki M, et al. Treatment of mediastinal lymphatic malformation in children: an analysis of a nationwide survey in Japan. Surg Today. 2018 Jul. 48 (7):716-725. [View Abstract]
  3. Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds JL Jr, Hoffer FA, et al. Lymphatic malformations: current cellular and clinical investigations. Otolaryngol Head Neck Surg. 2010 Jun. 142 (6):789-94. [View Abstract]
  4. Lajeunesse C, Stadler A, Trombert B, Varlet MN, Patural H, Prieur F, et al. [First-trimester cystic hygroma: prenatal diagnosis and fetal outcome]. J Gynecol Obstet Biol Reprod (Paris). 2014 Jun. 43 (6):455-62. [View Abstract]
  5. Sanhal CY, Mendilcioglu I, Ozekinci M, Yakut S, Merdun Z, Simsek M, et al. Prenatal management, pregnancy and pediatric outcomes in fetuses with septated cystic hygroma. Braz J Med Biol Res. 2014 Sep. 47 (9):799-803. [View Abstract]
  6. Tanna N, Sidell D, Schwartz AM, Schessel DA. Cystic lymphatic malformation of the middle ear. Ann Otol Rhinol Laryngol. 2008 Nov. 117 (11):824-6. [View Abstract]
  7. Bloom DC, Perkins JA, Manning SC. Management of lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg. 2004 Dec. 12 (6):500-4. [View Abstract]
  8. Kuang-Tao Y. Detection of chylothorax and cervical cystic hygroma in hydrops fetalis using lymphoscintigraphy. Clin Nucl Med. 2006 Apr. 31 (4):205-6. [View Abstract]
  9. Dries AM, McDermott J. Diagnosis of cystic lymphangioma of the pancreas with endoscopic ultrasound-guided fine needle aspiration. Am J Gastroenterol. 2008 Apr. 103 (4):1049-50. [View Abstract]
  10. Mulliken JB, Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg. 1982 Jul. 70 (1):120-1. [View Abstract]
  11. Giguère CM, Bauman NM, Smith RJ. New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol. 2002 Dec. 111 (12 Pt 1):1066-75. [View Abstract]
  12. de Serres LM, Sie KC, Richardson MA. Lymphatic malformations of the head and neck. A proposal for staging. Arch Otolaryngol Head Neck Surg. 1995 May. 121 (5):577-82. [View Abstract]
  13. Acevedo JL, Shah RK, Brietzke SE. Nonsurgical therapies for lymphangiomas: a systematic review. Otolaryngol Head Neck Surg. 2008 Apr. 138 (4):418-24. [View Abstract]
  14. [Guideline] Heit JJ, Do HM, Prestigiacomo CJ, Delgado-Almandoz JA, English J, Gandhi CD, et al. Guidelines and parameters: percutaneous sclerotherapy for the treatment of head and neck venous and lymphatic malformations. J Neurointerv Surg. 2017 Jun. 9 (6):611-617. [View Abstract]
  15. Wheeler JS, Morreau P, Mahadevan M, Pease P. OK-432 and lymphatic malformations in children: the Starship Children's Hospital experience. ANZ J Surg. 2004 Oct. 74 (10):855-8. [View Abstract]
  16. Peters DA, Courtemanche DJ, Heran MK, Ludemann JP, Prendiville JS. Treatment of cystic lymphatic vascular malformations with OK-432 sclerotherapy. Plast Reconstr Surg. 2006 Nov. 118 (6):1441-6. [View Abstract]
  17. Niramis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg. 2010 May. 20 (3):178-82. [View Abstract]
  18. Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg. 2011 May. 127 (5):2031-44. [View Abstract]
  19. Impellizzeri P, Romeo C, Borruto FA, Granata F, Scalfari G, De Ponte FS, et al. Sclerotherapy for cervical cystic lymphatic malformations in children. Our experience with computed tomography-guided 98% sterile ethanol insertion and a review of the literature. J Pediatr Surg. 2010 Dec. 45 (12):2473-8. [View Abstract]
  20. Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol. 2012 Sep. 42 (9):1080-8. [View Abstract]
  21. Koshy JC, Eisemann BS, Agrawal N, Pimpalwar S, Edmonds JL. Sildenafil for microcystic lymphatic malformations of the head and neck: A prospective study. Int J Pediatr Otorhinolaryngol. 2015 Jul. 79 (7):980-2. [View Abstract]
  22. Lackner H, Karastaneva A, Schwinger W, Benesch M, Sovinz P, Seidel M, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015 Dec. 174 (12):1579-84. [View Abstract]
  23. Alemi AS, Rosbe KW, Chan DK, Meyer AK. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations. Int J Pediatr Otorhinolaryngol. 2015 Dec. 79 (12):2466-9. [View Abstract]
  24. Yesil S, Tanyildiz HG, Bozkurt C, Cakmakci E, Sahin G. Single-center experience with sirolimus therapy for vascular malformations. Pediatr Hematol Oncol. 2016 Apr. 33 (3):219-25. [View Abstract]
  25. Wiegand S, Wichmann G, Dietz A. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review. Lymphat Res Biol. 2018 Aug. 16 (4):330-339. [View Abstract]
  26. García-Montero P, Del Boz J, Baselga-Torres E, Azaña-Defez JM, Alcaraz-Vera M, Tercedor-Sánchez J, et al. Use of topical rapamycin in the treatment of superficial lymphatic malformations. J Am Acad Dermatol. 2019 Feb. 80 (2):508-515. [View Abstract]
  27. Ozen IO, Moralioglu S, Karabulut R, Demirogullari B, Sonmez K, Turkyilmaz Z, et al. Surgical treatment of cervicofacial cystic hygromas in children. ORL J Otorhinolaryngol Relat Spec. 2005. 67 (6):331-4. [View Abstract]
  28. Burezq H, Williams B, Chitte SA. Management of cystic hygromas: 30 year experience. J Craniofac Surg. 2006 Jul. 17 (4):815-8. [View Abstract]
  29. Kim SW, Kavanagh K, Orbach DB, Alomari AI, Mulliken JB, Rahbar R. Long-term outcome of radiofrequency ablation for intraoral microcystic lymphatic malformation. Arch Otolaryngol Head Neck Surg. 2011 Dec. 137 (12):1247-50. [View Abstract]

Reconstruction of CT in sagittal dimension. This patient was intubated because of respiratory distress caused by the large lymphatic malformation.

Reconstruction of CT in sagittal dimension. This patient was intubated because of respiratory distress caused by the large lymphatic malformation.